Loading clinical trials...
Loading clinical trials...
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
Conditions
Interventions
nab-sirolimus
Locations
166
United States
Alabama Oncology
Birmingham, Alabama, United States
Southern Cancer Center
Mobile, Alabama, United States
Arizona Oncology Associates
Goodyear, Arizona, United States
Honor Health
Phoenix, Arizona, United States
Arizona Oncology Associates
Prescott Valley, Arizona, United States
Yuma Regional Medical Center
Yuma, Arizona, United States
Start Date
February 15, 2022
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2025
Last Updated
June 3, 2024
NCT04570423
NCT06132828
NCT07539441
NCT06144671
NCT06926283
NCT07177937
Lead Sponsor
Aadi Bioscience, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions